Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

DRAXIS Specialty Pharmaceuticals (formerly DRAXIS Health) lights up your insides with its own radiopharmaceuticals, but its main business is making other drug companies' injectable drugs, lotions and pills. The company's larger DRAXIS Pharma unit is a contract manufacturer specializing in liquid and freeze-dried injectable drugs, though it also makes sterile and non-sterile ointments, creams, and other formulations. Another unit, DRAXIMAGE, develops and makes radiopharmaceuticals, such as radioactive iodine, for use in diagnostic and therapeutic nuclear medicine procedures. DRAXIMAGE sells its products mostly in the US and Canada. In 2008 India-based Jubilant Organosys acquired DRAXIS for about $255 million.

TargeGen is developing small molecule therapeutics to treat cancer and cardiovascular disease. The development-stage firm's lead drug candidate, TG 100-115, could prevent complications after heart attacks. Other therapies in TargeGen's pipeline include a potential treatment for colorectal cancer, non-small cell lung cancer, and macular degeneration, an eye condition that often leads to blindness. The biotech company had been eying an IPO but opted in mid-2005 to stay private and took on an additional round of venture capital financing to fund trials of TG 100-115.

The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey. The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine calcium channel blocker, for the control of high blood pressure. The company's development products include cangrelor, an injectable antiplatelet agent that prevents platelet activation and aggregation in the clotting process; Oritavancin, a semi-synthetic lipoglycopeptide antibiotic for the treatment of gram-positive infections; and CU-2010 for the prevention of blood loss during surgery. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The Medicines Company sells its products through sales representatives and managers. The company has commercial supply agreement with Lonza Braine S.A. for the development and supply of the Angiomax bulk drug substance.

Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.Oxagen was established in April 1997 and initially focused on identifying drug targets through genetics. Since 2003 the Company has focused on building a drug discovery and development capability and pipeline around GPCR targets. Oxagen’s lead compound OC000459 is a novel oral anti-inflammatory agent for the treatment of allergic disease and has successfully completed Phase IIa trials demonstrating efficacy in both asthma and allergic rhinitis. Phase IIb dose-range finding studies are currently underway. The Company is based in Milton Park, south of Oxford.

Flamel Technologies S.A. was founded in 1990 and is headquartered in Venissieux, France. Flamel Technologies S.A., a biopharmaceutical company, engages in the development of polymer-based drug delivery technologies for the improvement of medical applications in France. Its Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides, and other large and small molecules injected subcutaneously. The company's Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking, and bioavailability enhancement. Its products based on Medusa technology include Interferon-AlphaXL, an interferon-alpha 2b for the treatment of hepatitis C virus and various oncology applications; FT-105 basal insulin, a long-acting formulation of recombinant human insulin to insulin-dependent patients; and interleukin-2 for the treatment of renal cancer. The company's products based on Micropump technology comprise Coreg CR, an extended release formulation of carvedilol phosphate for use in the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction, and hypertension; and Asacard162.5mg, a controlled release formulation of aspirin, which provide therapy for cardiovascular treatment. It has strategic alliances with GlaxoSmithKline, Merck Serono, Wyeth Pharmaceuticals, Pfizer, Corning S.A., Servier, and Corning Incorporated.

Celgene Signal Research (also known as Celgene Research San Diego) wouldn't want it any other way. This Celgene division works to identify potential drug candidates with a focus on regulating genes and the production of disease-causing proteins. Much of its work has been to identify and map certain kinase and ligase proteins, which future Celgene drugs are then designed to inhibit. Celgene Signal Research's drug discovery programs target inflammatory diseases, as well as cancers such as leukemia.

Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group Roche owns about 60% of Chugai Pharmaceutical.

EquiTech Corporation company focuses on improving the effectiveness of commonly used drugs primarily by enhancing the absorbtion of the drugs. Its ZAG-1701 is a fast-acting ibuprofen pill designed to treat pain, including dental, fractural, and post-operative incision pain as well as migraines and other headaches. EquiTech has a strategic partnership with fellow Canadian company Ethypharm Inc., developer and manufacturer of drug delivery systems. EquiTech company was founded by chief scientific officer Fakhreddin Jamali after he discovered that absorption of pain medication is slowed when a patient is in pain.

The Medical Research Council (MRC) is a not-for-profit UK government-financed organization that promotes and funds medical and other health-related research. Founded in 1913, MRC funding has been responsible for some of the biggest breakthroughs in life sciences, such as the purification of penicillin and the development of magnetic resonance imaging (MRI) technology. The council's funding is distributed to researchers in universities, the National Health System, and MRC research centers. Current research priorities include AIDS, antibiotic resistance, the use of animals in research, chronic fatigue syndrome, the study of cognitive systems, intensive care, multiple sclerosis, and other areas of public health.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.